Welcome to CARBOGEN AMCIS, a member of the Dishman Carbogen Amcis Group. We provide drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products produced at our facility in The Netherlands. These products are used in a variety of markets around the globe.
Our focus is to help customers create a better world by becoming the partner of choice for development and manufacture. The guiding principles for our service are our passion for great science supported by timely communication and backed by our total commitment to YOUR project.
We forge close collaboration and open communication with our customers which ensures we work effectively as a team, meeting (if not exceeding) our customers' expectations. We aim to manufacture pharmaceutical ingredients at the highest standard of GMP whilst protecting the environment.
We are a partner you can trust and we look forward to helping you move your project faster to the market!
With over 30 years’ experience, we have supported the pharmaceutical and biopharmaceutical industries with drug development and bringing new drugs to market to improve human health.
CARBOGEN AMCIS was born out of CarboGen, founded in 1990 at the University of Zurich and also AMCIS which was founded in 1982. The companies were both acquired by Solutia in 2000 and merged into the single legal entity now known as CARBOGEN AMCIS AG. Since then, we have continued to grow organically, and employ more than 600 people.
In August 2006, CARBOGEN AMCIS AG was acquired by Dishman Carbogen Amcis Ltd. (previously known as Dishman Pharmaceuticals and Chemicals Limited,) – allowing us within the Dishman Carbogen Amcis group to provide our customers with a fully flexible and effective customised delivery strategy for the entire life of a compound. This partnership has enabled CARBOGEN AMCIS to maintain its position as an industry leader and outsourcing partner for complex highly potent APIs and ADCs.
Foundation of AMCIS (Bubendorf) as joint venture with a pharmaceutical company in USA
Foundation Dishman Pharmaceutical and Chemicals Ltd
First Quats production facility established in Naroda
Foundation CarboGen (Aarau) as Spin-off of the University of Zurich focused and early-phase API supply
First production facility for bulk intermediates and API established in Bavla
Creation of Dishman Europe and Dishman USA subsidiaries
Acquisition of CarboGen and AMCIS by Solutia
Acquisition of the Manchester site
Creation of CARBOGEN AMCIS AG and acquisition by Dishman Pharmaceuticals and Chemicals Ltd
Formation of Dishman Japan and Dishman China. Acquisition of Dishman Netherlands
Integration of the Manchester site into CARBOGEN AMCIS
Acquisition of Riom (France) site CARBOGEN AMCIS SAS
Established Dishman Care
Acquisition of the Vionnaz (CH) site CARBOGEN AMCIS
Integration of the Shanghai site into CARBOGEN AMCIS
Company name changed to Dishman Carbogen Amcis Limited
Integration of the Veenendaal site into CARBOGEN AMCIS
Chief Executive Officer (CEO)
External President of the Board & Legal Council
Stephan Fritschi, Ph.D.
Vice President Operations
Alan Fischer, Ph.D.
Vice President Supply Chain & Enabling
Global Head HR
Martin Schneider, Ph.D.
Director Quality & ESH, Chief Quality Officer
Site Director/Director Technical Operations for Manchester
Marc Bertaud Ph.D.
Site Manager/Qualified Person for Riom
VP Operations for Veenendaal